What Are Sleeping Pill Side Effects?
What Are Sleeping Pill Side Effects? Insomnia can be a disruptive condition that affects your entire life. When you aren’t able to sleep at night, it can negatively impact issues in almost every area of your life and well-being. If you are taking sleeping pills or are thinking about starting to take sleeping pills, make sure you know as much as possible about all the sleeping pill side effects. What Are Sleeping Pills and How Do They Work? Sleeping pills are used to treat insomnia. According to the National Sleep Foundation, insomnia is described as difficulty falling asleep or staying asleep, even when a person has the chance to do so. People with insomnia can feel dissatisfied with their sleep and usually experience one or more of the following symptoms: fatigue, low energy, difficulty concentrating, mood disturbances, and decreased performance at work or at school. It is the most common sleep disorder in the US and impacts nearly 40 million people annually. Sleeping pills can be a helpful tool to help insomnia sufferers finally get a good night’s sleep and the rest that their body desperately needs. Although sleeping pills help treat insomnia, they are not a cure and usually, there are underlying issues that must be dealt with. Sleeping pills aren’t a cure for insomnia and shouldn’t be used long-term due to the many dangerous sleeping pill side effects. Sleeping Pill Side Effects Physical Sleeping Pill Side Effects One of the first sleeping pill sid...
There is good news and bad news when it comes to our understanding of inflammation in the pathogenesis and treatment of major depressive disorder (MDD). The bad news is that, like the dexamethasone suppression test or the efficacy of antidepressants before it, inflammation is oversold as an answer to the mystery of depression and its treatment. The good news is that an unusually replicable set of findings (for psychiatry) increasingly paints a consistent picture of the ways in which inflammation is of value in understanding MDD.
Challenges to the diagnosis and treatment of patients with psychiatric disorders have long been acknowledged in the field. In recent years, efforts have been made to identify genomic biomarkers for psychiatric disorders. A link between immune function and major depressive disorder (MDD) has been suggested for decades (1), but the identification of differentially expressed genes (DEGs) that underlie immune function as biomarkers for MDD has been more recent. Hundreds of DEGs have been reported for transcriptome-wide association studies (TWASs) of MDD.
Our brains are built to consider and reflect on the unknown. These adaptive features protect us from potential threats in dynamic and complex environments, but they can also lead us to perseverate on perceived threats and fear an unknown future. Ranging across a spectrum from adaptive to maladaptive, anxious and fearful behavior exists in many animal species. In an effort to develop new therapeutics and understand the etiology of anxiety-related conditions, such as anxiety disorders, obsessive-compulsive disorder, panic disorder, and posttraumatic stress disorder, research using laboratory animal models has focused on the ...
to: “Major Depressive Disorder Is Associated With Differential Expression of Innate Immune and Neutrophil-Related Gene Networks in Peripheral Blood: A Quantitative Review of Whole-Genome Transcriptional Data From Case-Control Studies,” by Wittenberg et al. (Biol Psychiatry 2020; 88:625–637); http s://doi.org/10.1016/j.biopsych.2020.05.006.
CONCLUSIONS: Glecaprevir/pibrentasvir was effective and well tolerated in treatment-naïve Brazilian patients with hepatitis C infection without cirrhosis and with compensated cirrhosis. TRIAL REGISTRATION: ClinicalTrials.gov NCT03219216. PMID: 32949786 [PubMed - as supplied by publisher]
Decline in global cognitive z - score faster for individuals with ≤ 4 hours, ≥ 10 hours of sleep nightly
Abstract Pulmonary comorbidities and ASA physical status class III and IV can significantly increase the rate of major complications after ISC placement. Patients with an underlying pulmonary comorbidity or lung disease (chronic obstructive pulmonary disease, asthma, or obstructive sleep apnea) have a 2.2-fold increased risk of having any complication and a 2.4-fold increased risk of having a major pulmonary complication compared to those without pulmonary comorbidities. Patients with pulmonary comorbidities may benefit from alternative pain management strategies to avoid complications in the early postoperative p...
Sep 30, 2020. . Sponsored by Center on Rural Addiction, University of Vermont
Publication date: Available online 20 September 2020Source: Journal of Theoretical BiologyAuthor(s): Courtney Cochrane, Melissa A. St. Hilaire, Demba Ba
More News: Addiction | Alcoholism | Allergy & Immunology | Anxiety | Brain | Caffeine | Cardiology | Depression | Environmental Health | Gastroenterology | Headache | Heart | HIV AIDS | Insomnia | Laboratory Medicine | Migraine | Neurology | Overdose | Sleep Disorders | Sleep Medicine | Sports Medicine | Substance Abuse | Substance Abuse Disorders | Sugar